广泛期小细胞肺癌应用伊立替康化疗中UGT1A1的表达及检测价值  

The value of the expression and detection of extensive stage small cell lung cancer with irinotecan chemotherapy in UGT1A1

作　　者：王晓红[1] 姚淑晖 闫淑静[1] 张静[1] 李义慧[1] 张瑞娟[1] 

机构地区：[1]唐山市人民医院放化科,河北唐山063001

出　　处：《临床医药文献电子杂志》2016年第49期9682-9682,9684,共2页Electronic Journal of Clinical Medical Literature

摘　　要：目的 探讨广泛期小细胞肺癌应用伊立替康化疗中UGT1A1的表达及检测价值.方法 选取2012年1月-2014年1月我院收治的广泛期小细胞肺癌患者42例,提取患者基因组DNA,采用PCR手段扩增患者目的基因片段,用直接测序法分析UGT1A1^＊28和UGT1A1^＊6多态性分布.应用伊立替康化疗化疗方案对患者进行治疗,比较分析不同基因型的治疗效果.结果 不同UGT1A1基因类型的SCLC患者的近期疗效比较,差异无统计学意义（P〉0.05）;不同UGT1A1基因类型的SCLC患者的化疗不良反应比较,差异有统计学意义（P〈0.05）.结论 UGT1A1基因多态性可以预测伊立替康化疗的不良反应,但对治疗疗效无法判定.Abstract The value of expression and detection of extensive stage small cell lung cancer with irinotecan chemotherapy in UGT1A1. Methods 42 patients with extensive stage small cell lung cancer who were treated in our hospital from January 2012 to January were selected,Extraction patient gnnomic DNA, using PCR method to amplify the target gene fragmant, The distribution of UGT1A1^＊28 and UGT1A1^＊6 polymorphism was analyzed by direct sequencing.For the treatment of patients with irinotecan chemotherapy regimen, comparative analysis of different genotypes of therapeutic effect. Results Comparison of short term efficacy of SCLC patients with different UGT1A1 gene types,The difference was not statistically significant （P〉0.05）. Comparison of adverse drug reactions in SCLC patients with different UGT1A1 gene types,The difference was statistically significant （P〈0.05）. Conclusion The adverse reaction of UGT1A1 gene polymorphism can predict irinotecan chemotherapy, But the curative effect can not be determined.

关 键 词：广泛期 小细胞肺癌 伊立替康 基因多态性 

分 类 号：R734.2[医药卫生—肿瘤]